PL3113774T3 - Kompozycje grapiprantu i sposoby ich zastosowania - Google Patents
Kompozycje grapiprantu i sposoby ich zastosowaniaInfo
- Publication number
- PL3113774T3 PL3113774T3 PL15758877T PL15758877T PL3113774T3 PL 3113774 T3 PL3113774 T3 PL 3113774T3 PL 15758877 T PL15758877 T PL 15758877T PL 15758877 T PL15758877 T PL 15758877T PL 3113774 T3 PL3113774 T3 PL 3113774T3
- Authority
- PL
- Poland
- Prior art keywords
- grapiprant
- compositions
- methods
- same
- Prior art date
Links
- HZVLFTCYCLXTGV-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical group CCC1=NC2=C(C)N=C(C)C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 HZVLFTCYCLXTGV-UHFFFAOYSA-N 0.000 title 1
- 229950004517 grapiprant Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461948957P | 2014-03-06 | 2014-03-06 | |
| US201462089713P | 2014-12-09 | 2014-12-09 | |
| EP15758877.3A EP3113774B1 (en) | 2014-03-06 | 2015-03-05 | Compositions of grapiprant and methods for using the same |
| PCT/US2015/019037 WO2015134792A1 (en) | 2014-03-06 | 2015-03-05 | Compositions of grapiprant and methods for using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3113774T3 true PL3113774T3 (pl) | 2022-06-13 |
Family
ID=54016294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15758877T PL3113774T3 (pl) | 2014-03-06 | 2015-03-05 | Kompozycje grapiprantu i sposoby ich zastosowania |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11369621B2 (pl) |
| EP (1) | EP3113774B1 (pl) |
| JP (1) | JP6419857B2 (pl) |
| KR (1) | KR102270323B1 (pl) |
| CN (2) | CN105939713A (pl) |
| AU (1) | AU2015227059B2 (pl) |
| CA (1) | CA2941008C (pl) |
| DK (1) | DK3113774T3 (pl) |
| ES (1) | ES2907285T3 (pl) |
| MX (3) | MX2016011025A (pl) |
| PL (1) | PL3113774T3 (pl) |
| PT (1) | PT3113774T (pl) |
| RU (1) | RU2679631C2 (pl) |
| TW (2) | TWI664969B (pl) |
| WO (1) | WO2015134792A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220096501A1 (en) * | 2014-12-09 | 2022-03-31 | Aratana Therapeutics, Inc. | Compositions of grapiprant and methods for using the same |
| US20210315909A1 (en) * | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| US20210353648A1 (en) * | 2018-09-27 | 2021-11-18 | Arrys Therapeutics, Inc. | Grapiprant unit dosage forms |
| CN115697317A (zh) * | 2020-04-08 | 2023-02-03 | 株式会社AskAt | Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ2479A1 (fr) * | 1997-05-05 | 2003-02-01 | Pfizer | Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant. |
| DE60012751T2 (de) * | 1999-08-10 | 2005-01-20 | Glaxo Group Ltd., Greenford | Verwendung von EP 4 Rezeptorliganden zur Behandlung von neuropathischem Schmerz |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| JP2005511562A (ja) * | 2001-10-31 | 2005-04-28 | メディカル リサーチ カウンシル | 月経困難症及び月経過多の治療のためのプロスタグランジンレセプターｅｐ２及び／又はｅｐ４のアンタゴニスト |
| IL164263A0 (en) | 2002-04-12 | 2005-12-18 | Pfizer | Use of ep4 receptor ligands on the treatment of il-6 involved diseases |
| WO2005102389A2 (en) * | 2004-04-20 | 2005-11-03 | Pfizer Products Inc. | Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists |
| PL1861400T3 (pl) * | 2005-03-11 | 2010-09-30 | Askat Inc | Postacie krystaliczne pochodnych imidazolu |
| EP2013169B1 (en) * | 2006-04-24 | 2012-08-22 | Merck Canada Inc. | Indole amide derivatives as ep4 receptor antagonists |
| US20080242713A1 (en) * | 2007-03-28 | 2008-10-02 | Bayer Schering Pharma Aktiengesellschaft | Novel 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases |
| KR101780666B1 (ko) | 2010-02-22 | 2017-09-21 | 에스크엣 인크. | Ｉｌ-23 매개 질환의 치료에서 ｅｐ4 수용체 길항제의 용도 |
| US20130225609A1 (en) * | 2010-04-08 | 2013-08-29 | Boehringer Ingelheim International Gmbh | Combinations of medicaments, containing pde4-inhibitors and ep4-receptor-antagonists |
| ES2639617T3 (es) * | 2010-10-12 | 2017-10-27 | Merz Pharma Gmbh & Co. Kgaa | Formulación adecuada para estabilizar proteínas, que carece de excipientes de mamíferos |
| MX2013010306A (es) * | 2011-03-08 | 2013-12-09 | Zalicus Pharmaceuticals Ltd | Formulaciones de dispersion solida y metodos de uso de las mismas. |
| CN103702995B (zh) | 2011-05-18 | 2016-04-13 | 拉夸里亚创药株式会社 | 4-{[4-({[4-(2,2,2-三氟乙氧基)-1,2-苯并异噁唑-3-基]氧}甲基)哌啶-1-基]甲基}-四氢-2h-吡喃-4-羧酸的多晶型形式 |
| ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
| CN107496421A (zh) | 2013-03-19 | 2017-12-22 | 株式会社ＡｓｋＡｔ | Ep4受体拮抗剂在软骨疾病的治疗中的用途 |
| PT3113773T (pt) | 2014-03-06 | 2019-11-12 | Aratana Therapeutics Inc | Formas cristalinas do grapiprant |
-
2015
- 2015-03-05 KR KR1020167027433A patent/KR102270323B1/ko active IP Right Grant
- 2015-03-05 PT PT157588773T patent/PT3113774T/pt unknown
- 2015-03-05 TW TW104107084A patent/TWI664969B/zh active
- 2015-03-05 CA CA2941008A patent/CA2941008C/en active Active
- 2015-03-05 EP EP15758877.3A patent/EP3113774B1/en active Active
- 2015-03-05 PL PL15758877T patent/PL3113774T3/pl unknown
- 2015-03-05 DK DK15758877.3T patent/DK3113774T3/da active
- 2015-03-05 JP JP2016573691A patent/JP6419857B2/ja active Active
- 2015-03-05 RU RU2016137926A patent/RU2679631C2/ru active
- 2015-03-05 AU AU2015227059A patent/AU2015227059B2/en active Active
- 2015-03-05 WO PCT/US2015/019037 patent/WO2015134792A1/en active Application Filing
- 2015-03-05 CN CN201580006168.6A patent/CN105939713A/zh active Pending
- 2015-03-05 ES ES15758877T patent/ES2907285T3/es active Active
- 2015-03-05 CN CN202011270789.4A patent/CN112370450A/zh active Pending
- 2015-03-05 US US14/639,898 patent/US11369621B2/en active Active
- 2015-03-05 TW TW106126404A patent/TWI708606B/zh active
- 2015-03-05 MX MX2016011025A patent/MX2016011025A/es active IP Right Grant
-
2016
- 2016-05-02 US US15/144,609 patent/US20160317559A1/en not_active Abandoned
- 2016-08-24 MX MX2022014763A patent/MX2022014763A/es unknown
- 2016-08-24 MX MX2020001428A patent/MX2020001428A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20160317559A1 (en) | 2016-11-03 |
| PT3113774T (pt) | 2022-02-28 |
| ES2907285T3 (es) | 2022-04-22 |
| NZ761827A (en) | 2021-03-26 |
| EP3113774A1 (en) | 2017-01-11 |
| AU2015227059B2 (en) | 2018-11-15 |
| RU2016137926A (ru) | 2018-04-09 |
| WO2015134792A1 (en) | 2015-09-11 |
| RU2019102384A (ru) | 2019-03-04 |
| CN112370450A (zh) | 2021-02-19 |
| KR102270323B1 (ko) | 2021-06-29 |
| CA2941008A1 (en) | 2015-09-11 |
| MX2016011025A (es) | 2016-11-29 |
| NZ724007A (en) | 2021-02-26 |
| JP2017507190A (ja) | 2017-03-16 |
| TW201603812A (zh) | 2016-02-01 |
| KR20160129887A (ko) | 2016-11-09 |
| TW201815393A (zh) | 2018-05-01 |
| RU2679631C2 (ru) | 2019-02-12 |
| RU2019102384A3 (pl) | 2022-03-31 |
| JP6419857B2 (ja) | 2018-11-07 |
| EP3113774A4 (en) | 2017-10-25 |
| MX2020001428A (es) | 2020-03-20 |
| US11369621B2 (en) | 2022-06-28 |
| TWI664969B (zh) | 2019-07-11 |
| CA2941008C (en) | 2022-07-26 |
| EP3113774B1 (en) | 2022-01-26 |
| CN105939713A (zh) | 2016-09-14 |
| DK3113774T3 (da) | 2022-03-07 |
| AU2015227059A1 (en) | 2016-09-22 |
| US20150250773A1 (en) | 2015-09-10 |
| MX2022014763A (es) | 2023-01-11 |
| TWI708606B (zh) | 2020-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192145T1 (hr) | Pripravci nosača-antitijela i metode pripreme i uporabe istih | |
| HK1257295A1 (zh) | 用於免疫腫瘤學的組合物和方法 | |
| GB2535253B (en) | Compositions and methods | |
| GB2546350B (en) | Compositions and methods | |
| GB2535423B (en) | Cementing compositions and methods | |
| HUE056172T2 (hu) | Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra | |
| GB201718876D0 (en) | Antithrombin-heparin compositions and methods | |
| IL246879A0 (en) | Preparations of Epilimod and methods of using them | |
| GB201417828D0 (en) | New methods and compositions | |
| ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
| HK1245158A1 (zh) | 阿吡莫德組合物及其使用方法 | |
| EP3166892A4 (en) | Scale-inhibition compositions and methods of making and using the same | |
| HK1246193A1 (zh) | 用於改善認知的方法和組合物 | |
| HK1247136A1 (zh) | 包含15-hepe的組合物和其使用方法 | |
| PL3113774T3 (pl) | Kompozycje grapiprantu i sposoby ich zastosowania | |
| HK1243404A1 (zh) | 色酰胺組合物和使用方法 | |
| GB201512996D0 (en) | Compositions and methods | |
| ZA201606594B (en) | Defoamer compositions and methods of using the same | |
| GB201514413D0 (en) | Compositions and methods | |
| GB201402915D0 (en) | Compositions and methods | |
| IL256261B (en) | Hide1 compositions and methods | |
| GB201522554D0 (en) | Methods and compositions | |
| GB201518167D0 (en) | Methods and compositions | |
| GB201514415D0 (en) | Compositions and methods | |
| GB201403212D0 (en) | Compositions and methods |